Co-Authors
This is a "connection" page, showing publications co-authored by JACK A ROTH and BINGLIANG FANG.
Connection Strength
4.048
-
The role of gene therapy in combined modality treatment strategies for cancer. Curr Opin Mol Ther. 2003 Oct; 5(5):475-82.
Score: 0.237
-
Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol. 2023 Jun 06; 6(1):608.
Score: 0.232
-
3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol. 2023 05 11; 6(1):509.
Score: 0.231
-
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res. 2020; 10(12):4464-4475.
Score: 0.195
-
Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer. 2019 11 01; 125(21):3738-3748.
Score: 0.177
-
An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer Immunol Res. 2019 08; 7(8):1267-1279.
Score: 0.176
-
Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. Am J Cancer Res. 2019; 9(6):1201-1211.
Score: 0.176
-
Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. Cancer Res. 2019 01 01; 79(1):125-132.
Score: 0.169
-
Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer. 2018 03 01; 124(5):1061-1069.
Score: 0.158
-
Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities. Oncotarget. 2017 Nov 24; 8(60):102150-102160.
Score: 0.157
-
Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy. Oncoimmunology. 2017; 7(1):e1376156.
Score: 0.157
-
TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin. Sci Rep. 2016 11 15; 6:35741.
Score: 0.147
-
Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget. 2016 Jan 19; 7(3):3548-58.
Score: 0.139
-
Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380. Oncotarget. 2015 Jan 01; 6(1):345-54.
Score: 0.129
-
Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 2015 Feb 01; 357(1):179-185.
Score: 0.128
-
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014 Sep; 106(9).
Score: 0.127
-
Prodrug oncrasin-266 improves the stability, pharmacokinetics, and safety of NSC-743380. Bioorg Med Chem. 2014 Oct 01; 22(19):5234-40.
Score: 0.126
-
The tumor suppressor gene TUSC2 (FUS1) sensitizes NSCLC to the AKT inhibitor MK2206 in LKB1-dependent manner. PLoS One. 2013; 8(10):e77067.
Score: 0.119
-
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Mol Cancer Ther. 2013 Dec; 12(12):2864-73.
Score: 0.119
-
Insulin-like growth factor binding protein-2 level is increased in blood of lung cancer patients and associated with poor survival. PLoS One. 2013; 8(9):e74973.
Score: 0.118
-
KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer. Cancer Res. 2013 Sep 01; 73(17):5532-43.
Score: 0.117
-
Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol. 2012 May 15; 83(10):1456-64.
Score: 0.106
-
STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res. 2011 May 15; 71(10):3658-68.
Score: 0.100
-
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One. 2010 Nov 29; 5(11):e14124.
Score: 0.097
-
Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis. Oncogene. 2004 Feb 12; 23(6):1300-7.
Score: 0.061
-
Insulin-like growth factor binding proteins increase intracellular calcium levels in two different cell lines. PLoS One. 2013; 8(3):e59323.
Score: 0.057
-
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts. Sci Rep. 2022 07 29; 12(1):12984.
Score: 0.055
-
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep. 2022 01 24; 12(1):1248.
Score: 0.053
-
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer. 2020 11; 149:33-40.
Score: 0.048
-
Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene. 2020 01; 39(4):801-813.
Score: 0.045
-
RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. Oncotarget. 2015 May 10; 6(13):11114-24.
Score: 0.033
-
Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC. J Thorac Oncol. 2013 Mar; 8(3):301-8.
Score: 0.028
-
GSH depletion enhances adenoviral bax-induced apoptosis in lung cancer cells. Cancer Gene Ther. 2004 Apr; 11(4):249-55.
Score: 0.015
-
Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells. Gynecol Oncol. 2002 Jun; 85(3):451-8.
Score: 0.014